SCHEMBL8227168

C=CCOC(=O)NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](N)Cc2c[nH]c3ccccc23)[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@H](C(C)CC(=O)O)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC1=O

nearest known ligand 0.74

Predicted protein targets (top 18)

	gene	UniProt	supporting neighbours	confidence
▸	CTSL	P07711	1/20	0.74

▸	DRD1	P21728	1/20	0.74

▸	PTGS1	P23219	1/20	0.74

▸	PDE4A	P27815	1/20	0.74

▸	EPHA2	P29317	3/20	0.39

▸	KDM4A	O75164	1/20	0.37

▸	F11	P03951	1/20	0.37

▸	TSLP	Q969D9	5/20	0.36

▸	NPR1	P16066	1/20	0.36

▸	NPR3	P17342	1/20	0.36

▸	TET2	Q6N021	1/20	0.36

▸	TET1	Q8NFU7	1/20	0.36

▸	KEAP1	Q14145	1/20	0.36

▸	PRLHR	P49683	2/20	0.36

▸	KLKB1	P03952	2/20	0.36

▸	ESR1	P03372	1/20	0.35

▸	ESR2	Q92731	1/20	0.35

▸	KRAS	P01116	1/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14446427	0.96	CTSL (0.76)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL14446086	0.96	CTSL (0.76)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL14446449	0.96	CTSL (0.74)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8236190	0.94	CTSL (0.66)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL15177399	0.94	CTSL (0.74)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8227349	0.93	CTSL (0.78)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8221933	0.93	CTSL (0.86)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8244573	0.93	CTSL (0.64)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8227371	0.93	CTSL (0.64)	CTSLDRD1PTGS1PDE4AEPHA2
SCHEMBL8354268	0.92	CTSL (0.86)	CTSLDRD1PTGS1PDE4AEPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20080119395-A1	Novel Depsipeptides and Process for Preparing Same	CUBIST PHARMACEUTICALS, INC.	2008-05-22	—	—	US	disclosed
US-7335726-B2	Lipopeptide stereoisomers, methods for preparing same and useful intermediates	CUBIST PHARMACEUTICALS, INC. (US)	2008-02-26	—	—	US	disclosed
US-7262268-B2	Lipopeptide stereoisomers, methods for preparing same, and useful intermediates	CUBIST PHARMACEUTICALS, INC. (US)	2007-08-28	—	—	US	disclosed
US-7262268-B2	Lipopeptide stereoisomers, methods for preparing same, and useful intermediates	CUBIST PHARMACEUTICALS, INC. (US)	2007-08-28	—	—	US	disclosed
US-20060223983-A1	Lipopeptide stereoisomers, methods for preparing same and useful intermediates	CUBIST PHARMACEUTICALS, INC.	2006-10-05	—	—	US	disclosed
US-20060194714-A1	Novel depsipeptides and process for preparing same	CUBIST PHARMACEUTICALS, INC.	2006-08-31	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20060194714-A1	Novel depsipeptides and process for preparing same	VIP, DNPEP, PREP	CTSL 124/4885DRD1 2758/4885PTGS1 4259/4885
US-20060223983-A1	Lipopeptide stereoisomers, methods for preparing same and useful intermediates	NGLY1, LSS, NRDC	CTSL 187/4885DRD1 3225/4885PTGS1 1577/4885
US-20080119395-A1	Novel Depsipeptides and Process for Preparing Same	VIP, DNPEP, PREP	CTSL 124/4885DRD1 2758/4885PTGS1 4259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.